Consolidated statements of changes in equity
(thousands of €) |
Share capital |
Share premium account |
Translation differences |
Other reserves |
Accumul. losses |
Total |
|---|---|---|---|---|---|---|
On 1 January 2018 |
233,414 |
993,025 |
(1,754) |
(1,260) |
(211,441) |
1,011,983 |
Change in accounting policy (modified retrospective application IFRS 15) |
|
|
|
|
(83,220) |
(83,220) |
Change in accounting policy (modified retrospective application IFRS 9) |
|
|
|
619 |
(619) |
– |
Restated total equity at 1 January 2018 |
233,414 |
993,025 |
(1,754) |
(641) |
(295,279) |
928,766 |
Net loss |
|
|
|
|
(29,259) |
(29,259) |
Other comprehensive income/loss (-) |
|
|
197 |
(94) |
|
103 |
Total comprehensive income/loss (-) |
|
|
197 |
(94) |
(29,259) |
(29,155) |
Share-based compensation |
|
|
|
|
26,757 |
26,757 |
Issue of new shares |
16,021 |
280,167 |
|
|
|
296,188 |
Share issue costs |
(15,964) |
|
|
|
|
(15,964) |
Exercise of warrants |
3,069 |
4,588 |
|
|
|
7,657 |
On 31 December 2018 |
236,540 |
1,277,780 |
(1,557) |
(735) |
(297,779) |
1,214,249 |
|
|
|
|
|
|
|
On 1 January 2019 |
236,540 |
1,277,780 |
(1,557) |
(735) |
(297,779) |
1,214,249 |
Change in accounting policy (modified retrospective application IFRS 16) |
|
|
|
|
416 |
416 |
Restated total equity at 1 January 2019 |
236,540 |
1,277,780 |
(1,557) |
(735) |
(297,363) |
1,214,665 |
Net profit |
|
|
|
|
149,845 |
149,845 |
Other comprehensive income/loss (-) |
|
|
415 |
(4,107) |
|
(3,692) |
Total comprehensive income/loss (-) |
|
|
415 |
(4,107) |
149,845 |
146,154 |
Share-based compensation |
|
|
|
|
38,297 |
38,297 |
Derecognition of financial liability from share subscription agreement and warrant A |
|
135,702 |
|
|
|
135,702 |
Issue of new shares |
36,945 |
923,142 |
|
|
|
960,087 |
Share issue costs |
(4,447) |
|
|
|
|
(4,447) |
Exercise of warrant A by Gilead |
14,162 |
353,873 |
|
|
|
368,035 |
Exercise of warrants |
4,082 |
13,085 |
|
|
|
17,167 |
On 31 December 2019 |
287,282 |
2,703,583 |
(1,142) |
(4,842) |
(109,223) |
2,875,658 |
The accompanying notes form an integral part of these financial statements.